Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Oregon: - Clackamas Radiation Oncology Center — Clackamas, Oregon
- Legacy Mount Hood Medical Center — Gresham, Oregon
- Legacy Good Samaritan Hospital and Medical Center — Portland, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
Phase 3 Recruiting Industry
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of sk…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06246916
Sites in Oregon: - Oncology Associates of Oregon PC — Eugene, Oregon
- Kaiser Foundation Hospitals — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
Phase 3 Recruiting Industry
This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a …
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06585410
Sites in Oregon: - Dermatology Health Specialists — Bend, Oregon
- Oregon Health & Science University — Portland, Oregon
Phase 3 Recruiting Industry
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommende…
Sponsor: Immatics US, Inc.
NCT ID: NCT06743126
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Oregon: - Saint Alphonsus Medical Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Oregon: - Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Newberg Medical Center — Newberg, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
Phase 2 Recruiting NIH
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05111574
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Oregon: - USA15-0 — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Oregon: - Providence Cancer Center Oncology and Hematology Care- Eastside — Portland, Oregon
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine the objective response of GB1211 and pembrolizumab versus pembrolizumab and placebo in patients with advance metastatic melanoma or head and neck squamous cell carcinoma.
Sponsor: Providence Health & Services
NCT ID: NCT05913388
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…
Sponsor: Pfizer
NCT ID: NCT05538130
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
- Providence Portland Medical Center — Portland, Oregon
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …
Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
- Providence Portland Medical Center — Portland, Oregon
EARLY Phase 1 Recruiting Industry
This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via …
Sponsor: Presage Biosciences
NCT ID: NCT04541108
Sites in Oregon: - Oregon Health & Science University (OHSU) — Portland, Oregon
Phase 1 Recruiting Industry
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…
Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Oregon: - Providence Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Sponsor: Novelty Nobility, Inc.
NCT ID: NCT06805825
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Kaiser Permanente Northwest — Portland, Oregon
Recruiting Network
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…
Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in Oregon: - Legacy Emanuel Children's Hospital — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
NA Recruiting Academic/Other
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1…
Sponsor: Melanoma and Skin Cancer Trials Limited
NCT ID: NCT03860883
Sites in Oregon: - Kaiser Sunnyside Medical Center — Clackamas, Oregon
- Kaiser Permanente Northwest - Oncology Clinic — Portland, Oregon
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oregon: - Massive Bio SYNERGY-AI site — Portland, Oregon
Recruiting Industry
The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences …
Sponsor: Aura Biosciences
NCT ID: NCT03941379
Sites in Oregon: - Oregon Health & Science University Casey Eye Institute — Portland, Oregon
NA Recruiting Academic/Other
This trial studies how well a health educational campaign works in increasing early detection of melanoma in Oregon. The health educational campaign may provide information to help people learn about the early signs of melanoma. Increased …
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT04611568
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
NA Recruiting Academic/Other
This clinical trial compares the effect of a narrow surgical excision (removal) to a wide excision for the treatment of adults with invasive cutaneous melanoma. Currently the standard of care is to take wide margins (boarder of healthy tis…
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT06673095
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
Recruiting Academic/Other
This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from healthy eyes will be compared to eyes with various types of iris tumors.
Sponsor: Oregon Health and Science University
NCT ID: NCT03809585
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon